Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA held a pre-IND meeting June 17 with Shanghai-based Hutchison MediPharma on its Phase I development plan for its solid tumor drug HMPL-012, the company told PharmAsia News
Advertisement

Related Content

Asia Spotlight: Meet China’s New Innovators – Hua Medicine Looks To Take Flight With U.S. Venture Backing
Meet China’s New Innovators: Hua Medicine Looks To Take Flight With U.S. Venture Backing (Part 1)
Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China
Novamed In-Licenses Products from Iroko and EUSA To Strengthen Cardiovascular And Oncology Pipeline
Chinese Vaccine Leader Sinovac Starts Preparations To Produce H1N1 Vaccine
J&J Expands R&D Force In Asia With Opening Of Shanghai R&D Center
China’s First HIV Vaccine Enters Phase II Clinical Trials
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
China’s Hutchison MediPharma Freezes Development Of Cancer Drug, Signs Development Deal With Janssen
Advertisement
UsernamePublicRestriction

Register

SC072023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel